Transforming growth factor beta (TGF-β) in adolescent chronic fatigue syndrome.
Wyller, Vegard Bruun, Nguyen, Chinh Bkrong, Ludviksen, Judith Anita et al. · Journal of translational medicine · 2017 · DOI
Quick Summary
This study tested whether a protein called TGF-β, which helps regulate immune and stress responses, was elevated in adolescents with ME/CFS. Researchers compared blood levels of TGF-β in 120 young ME/CFS patients to 68 healthy controls and found the protein levels were actually the same in both groups. However, they discovered that in ME/CFS patients, TGF-β levels were connected to stress hormones and fatigue severity, suggesting it may play a role in how the illness affects the body even if it's not simply 'too high.'
Why It Matters
This study addresses a key gap by testing the most consistent cytokine finding from decades of ME/CFS research. The discovery that TGF-β relates to neuroendocrine dysfunction and fatigue may help explain how immune-endocrine interactions contribute to ME/CFS symptoms, potentially opening new avenues for understanding disease mechanisms and monitoring response to treatment.
Observed Findings
Plasma levels of TGF-β1, TGF-β2, and TGF-β3 were statistically similar between adolescent ME/CFS patients and healthy controls.
Within the CFS group, all three TGF-β isoforms correlated with plasma cortisol and urinary norepinephrine and epinephrine levels.
The association between TGF-β levels and neuroendocrine markers was related to fatigue severity scores in the CFS group.
TGF-β3 showed associations with B cell-related gene expression (TNFRSF13C and CXCR5) in gene expression analysis.
Inferred Conclusions
TGF-β isoforms are not globally elevated in adolescent ME/CFS but function as markers of neuroendocrine dysregulation linked to fatigue severity.
TGF-β, particularly the TGF-β3 isoform, may partially mediate interactions between cortisol and B cell immune function.
The relationship between TGF-β and stress hormones suggests ME/CFS involves complex immune-neuroendocrine interactions rather than simple elevation of single cytokines.
Remaining Questions
Why do TGF-β isoforms correlate with neuroendocrine markers and fatigue in CFS patients when overall plasma levels are normal?
Does TGF-β play a functional role in driving neuroendocrine dysfunction, or is it merely a marker of underlying pathophysiology?
What This Study Does Not Prove
This study does not prove that TGF-β causes ME/CFS, nor does it establish whether the observed associations are primary features of the disease or secondary responses to fatigue and activity limitation. The cross-sectional design cannot determine causality, and the correlation between TGF-β and hormonal markers does not identify TGF-β as a driver of neuroendocrine dysfunction.